减量化疗肝动脉栓塞治疗肝癌合并梗阻性黄疸的研究

目的研究减量化疗肝动脉栓塞治疗伴有梗阻性黄疸原发性肝癌的安全性及疗效。方法回顾性分析24例首选减量化疗肝动脉栓塞治疗的伴有梗阻性黄疸的原发性肝癌病例。患者均为单个肿瘤。结果 24例患者中位生存期为9.0月,1、2、3年的生存率分别为33.3%、22.2%、16.6%。单因素及多因素生存分析显示,肿瘤大小及AFP水平是生存时间影响因素（P〈0.05）,总胆红素水平不是影响生存的因素（P〉0.05）。24例患者术前总胆红素水平平均为70.5μmol/L,术后1月33.2μmol/L,较术前明显下降（P=0.006）。所有患者均无严重并发症发生。结论首选减量化疗肝动脉栓塞治疗伴有梗阻性黄疸的原发性肝癌是安全、有效的。

Dose-reduced transarterial chemoembolization for primary liver cancer patients with obstructive jaundice

Objective To evaluate the safety and efficacy of dose-reduced transarterial chemoembolization（TACE）for primary liver cancer patients with obstructive jaundice.Methods Twenty-four primary liver cancer patients with single tumor and obstructive jaundice undergoing dose-reduced TACE were retrospectively analyzed.Results The overall median survival time of 24 patients was 9.0 months.The 1-,2-and 3-year cumulative survival rates were 33.3%,22.2% and16.6%.Tumor size and AFP level were significant predicting factors for the efficacy of therapy（P 〈 0.05）,but the level of total bilirubin was not（P 〉 0.05）.The 1-month post-operative total bilirubin level was significantly lower than the preoperative level（33.2 μmol/L vs 70.5 μmol/L,P = 0.006）.No severe complication occurred.Conclusion Dose-reduced TACE for primary liver cancer patients with obstructive jaundice is safe and effective.